This research is Trending!
August 1, 2026Journal of the American College of Cardiology
Implications of the 2026 Versus 2018 ACC/AHA Multisociety Dyslipidemia Guidelines on the Clinical Care of U.S. Adults
Key result
Updated dyslipidemia guidelines expand lipid-lowering therapy eligibility to ~41% of adults without ASCVD.
Why the study?
The 2026 ACC/AHA Multisociety Dyslipidemia Guideline introduced new risk calculators, thresholds, treatment targets, and recommendations based on long-term risk, requiring quantification of population-level implications compared to the 2018 guideline.
Does the 2026 ACC/AHA Multisociety Dyslipidemia Guideline increase the proportion of U.S. adults eligible for lipid-lowering therapy compared to the 2018 guideline?
Study Design
Type
Cross-Sectional
Structured PICO
Does the 2026 ACC/AHA Multisociety Dyslipidemia Guideline increase the proportion of U.S. adults eligible for lipid-lowering therapy compared to the 2018 guideline?
P
Population
U.S. adults aged ≥20 years without ASCVD, with LDL-C ≥70 mg/dL, and not on lipid-lowering therapy, representing an estimated 165.4 million individuals.
E
Exposure
Application of the 2026 ACC/AHA Multisociety Dyslipidemia Guideline recommendations (including new risk calculators, thresholds, treatment targets, and 30-year risk recommendations).
C
Comparator
Application of the 2018 ACC/AHA Multisociety Dyslipidemia Guideline recommendations.
O
Outcome
Proportion and number of U.S. adults eligible for initiation of lipid-lowering therapy and proportion meeting their 2026 treatment targets.
Main Result
Absolute Event Rate: 40.5% vs 25.7%
The 2026 ACC/AHA dyslipidemia guidelines substantially increase the number of U.S. adults eligible for statin therapy, primarily by incorporating 30-year ASCVD risk, while highlighting that most treated patients currently fail to meet the new, stricter LDL-C targets.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The 2026 [American Heart Association]/ACC dyslipidemia guideline expands the U.S. population eligible for statin therapy for primary prevention of ASCVD by an estimated 21 million individuals, resulting in more than half of nonpregnant adults aged 30 to 79 years now being primary prevention statin eligible, with the majority of newly eligible individuals having less than 3% estimated 10-year risk of ASCVD”
“By increasing the number of borderline-risk individuals and decreasing those at intermediate to high risk, the [2026 dyslipidemia guideline] shifts the focus to emerging risk markers, subclinical disease with coronary artery calcium scoring, and shared decision-making to guide cardiovascular prevention and lipid management”
PGPhilip GreenlandCardiologist and epidemiologist, Northwestern University
“confirm the long-standing observation that a large percentage of U.S. adults aged 30 years or older are candidates for guideline-directed LLT, and many who are currently taking LLT are not reaching new (or previous) LDL-C goals”
Implication
May broaden statin eligibility among younger adults without ASCVD; leaves open net clinical benefit pending prospective outcome data.
Abstract
BACKGROUND: The American College of Cardiology and American Heart Association recently updated their guidelines for dyslipidemia, which included recommending new risk calculators and thresholds, treatment targets, and treatment recommendations based on long-term risk. OBJECTIVES: The purpose of this study was to quantify the population-level implications of the 2026 Dyslipidemia Guideline. METHODS: Using data across 4 survey cycles from the 2011-2020 NHANES (National Health and Nutrition Examination Survey), we estimated the proportion and number of U.S. adults aged 20 years or older who were eligible for initiation of lipid-lowering therapy (LLT) under the 2026 vs 2018 guideline recommendations and the proportion meeting their 2026 treatment targets RESULTS: Among U.S. adults ≥20 years of age without atherosclerotic cardiovascular disease (ASCVD), with a low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL, and not on LLT (n = 165.4 million), 40.5% were eligible per the 2026 guideline vs 25.7% per the 2018 guideline, representing an additional 24.5 million adults. The largest contributor to the increase was the recommendation to consider statins in adults aged 30 to 59 years with a 30-year ASCVD risk ≥10% despite a 10-year risk <3%, based on which 15.6 million more adults would be eligible. In this age group, nearly twice as many qualify based on a 30-year ASCVD ≥10% vs 10-year ASCVD risk ≥3% (15.6 million vs 7.9 million). Among 39.1 million adults receiving LLT for a Class 1 indication, most (79.0%) had LDL-C above goal, including 91.1% of adults with ASCVD having LDL-C ≥55 mg/dL and 74.5% with LDL-C ≥70 mg/dL. CONCLUSIONS: Compared with the 2018 guideline, the 2026 American College of Cardiology/American Heart Association Multisociety Dyslipidemia Guideline substantially expanded the proportion of U.S. adults for whom statin therapy should be considered by extending recommendations to adults at high 30-year risk. Among those already on treatment, the vast majority remain above new guideline goals. Significant population-level shifts in statin initiation and therapy intensification will be needed to reach guideline goals at a national level.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Sayed et al. (2026) conducted a cross-sectional in Dyslipidemia. 2026 ACC/AHA Multisociety Dyslipidemia Guidelines vs. 2018 ACC/AHA Multisociety Dyslipidemia Guidelines was evaluated on Eligibility for initiation of lipid-lowering therapy. The 2026 dyslipidemia guidelines expanded eligibility for lipid-lowering therapy to 40.5% of U.S. adults without ASCVD compared to 25.7% under the 2018 guidelines.